key: cord-0948829-zeqtbn7e
authors: Amenta, Eva M; Spallone, Amy; Rodriguez-Barradas, Maria C; El Sahly, Hana M; Atmar, Robert L; Kulkarni, Prathit A
title: Post-Acute COVID-19: An Overview and Approach to Classification
date: 2020-10-21
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofaa509
sha: 9ced34684c38ea41f500ab74de8889a8ae454fd7
doc_id: 948829
cord_uid: zeqtbn7e

As the coronavirus disease 2019 (COVID-19) pandemic has progressed, a large volume of literature has developed delineating the clinical manifestations of acute infection. Recent reports have also started to describe persistent symptoms extending beyond the period of initial illness or hospitalization. Anecdotes of different signs and symptoms occurring after acute infection have also arisen in the lay press. Here we describe the current existing medical literature on the emerging concept of post-acute COVID-19 and suggest an approach to classifying different manifestations of the syndrome. We also review long-term clinical manifestations observed in patients who recovered from infection due to other epidemic coronaviruses and briefly discuss potential mechanisms driving the phenomenon of post-acute COVID-19.

A c c e p t e d M a n u s c r i p t Currently, the medical literature on the topic of post-acute COVID-19 includes reports of subjective post-acute symptoms in patients who recovered from a wide spectrum of acute COVID-19, including mild infection through critical illness. The literature also describes various findings of objective organ pathology following acute infection. Therefore, to standardize our current understanding of post-acute COVID-19, we propose dividing post-acute manifestations into 3 categories, as represented in Figure   1 : (1) residual symptoms that persist after recovery from acute infection; (2) organ dysfunction that persists after initial recovery; and (3) new symptoms or syndromes that develop after initial asymptomatic or mild infection. It is important to note that the first two categories outlined are not necessarily mutually exclusive. For example, dysfunction from one or multiple organ systems might result in certain symptoms patients experience; pulmonary pathology leading to persistent dyspnea or cough would be a prime example of this type of interplay.

It appears that fatigue is one of the most frequently reported symptoms that patients experience after recovery from acute SARS-CoV-2 infection. Carfi et al report persistent symptoms in 143 patients evaluated after hospitalization due to COVID-19 ( Table 1 ) [6] . All patients in this study were PCRnegative in the follow-up period. They note that 87% of patients had at least one persistent symptom at a mean of 60 days after symptom onset, with the most common symptoms being fatigue (53.1%), dyspnea (43.4%), and arthralgias (27.3%). Importantly, a majority of those with persistent symptoms, 55%, had 3 or more symptoms, while 32% had 1 or 2 symptoms, suggesting a high overall symptom burden.

Another survey study from the United Kingdom (UK) evaluated 100 patients with COVID-19 at a mean of 48 days after hospital discharge [7] . The survey was conducted by telephone using a standardized screening tool administered to all participants. Out of 100 surveyed patients, 32 had required admission to the intensive care unit (ICU). The median age among patients admitted to a general hospital ward was 70.5 years, while in the ICU population it was 58.5 years. A slight majority A c c e p t e d M a n u s c r i p t of patients, 54%, were male. New fatigue was more common among patients admitted to ICU (72%) than ward patients (60%). Although mild in severity, new or worsened breathlessness was more common among ICU patients (66%) than ward patients (43%). Almost half of patients admitted to ICU also reported symptoms of post-traumatic stress disorder (PTSD). Finally, new or worsened concentration problems were reported by 16% of ward patients and 34% of ICU patients. A summary of these findings is included in Table 1 .

In another single-center study from France, Garrigues et al performed telephone surveys of 120 hospitalized patients (96 on general hospital wards; 24 in ICU) at a mean follow-up of 110.9 days following admission (range 100-121 days) [8] . The most frequently reported symptoms in this study were fatigue (55%), dyspnea (42%), loss of memory (34%), concentration issues (28%), and sleep disorders (30.8%). There was no statistically significant difference in symptomatology between patients admitted to ICU and those admitted to general wards.

Post-acute symptomatology does not appear to occur only in those recovering from more severe forms of COVID-19. A report published by the Centers for Disease Control and Prevention (CDC) described persistent symptoms in patients with predominantly mild COVID-19 [9] . This study included 274 patients from around the United States who underwent SARS-CoV-2 testing either in the Emergency Department or outpatient clinics. Study participants were contacted by telephone at a median of 16 days following testing and underwent an interview using a standardized questionnaire. The median age of 274 respondents was 42.5 years, and a slight majority (52%) were female. Out of 270 patients for whom data were available, the most commonly reported persistent symptoms at the time of telephone interview were cough (43%), fatigue (35%), and dyspnea (29%). A total of 95 (35%) patients reported not having returned to their baseline state of health. There was also a statistically significant association between the presence of underlying chronic medical conditions and not returning to baseline state of health, with 28% of those with 0 to 1 chronic condition reporting this, A c c e p t e d M a n u s c r i p t 46% of those with 2 chronic conditions, and 57% among those with 3 or more chronic conditions (p = .003). Other risk factors for not having returned to usual state of health included obesity (adjusted odds ratio [aOR] of 2.31) and presence of an underlying psychiatric condition (aOR of 2.32). It should be noted that 19 of 262 patients (7%) in this study for whom data were available reported being hospitalized after initial testing.

Along with symptomatology, the myriad effects of acute COVID-19 on different organ systems have been well-described [10] . The persistence of organ dysfunction beyond the acute phase is now also beginning to be reported.

In the acute phase of infection with SARS-CoV-2, classifying disease severity relies predominantly on pulmonary pathology. A report of 72,314 patients from China noted that severe infection occurred in 10,123 (14%) patients and critical illness in 3,616 (5%) [11] . The acute respiratory distress syndrome (ARDS) is another clinical manifestation of severe or critical COVID-19. In one of the first reports describing 138 hospitalized patients from Wuhan, China, ARDS occurred in 27 patients (19.6%) [12] .

Regarding the post-acute period, in a study of 110 hospitalized patients with acute COVID-19, pulmonary function tests (PFTs) were performed either on the day of hospital discharge or 1 day prior [13] . This testing noted abnormalities in the diffusing capacity of the lung for carbon monoxide (DLCO), with 51/110 patients (47.2%) having <80% of predicted capacity. Reduction in DLCO was more frequently seen among patients who had experienced more severe disease. A total of 30.4%, 42.4%, and 84.2% among those with mild illness, pneumonia, and severe pneumonia, respectively, had impairment in DLCO (p = <.05). A description of patients' symptomatology was not provided in this study to correlate with objective findings. Additionally, a separate study of 13 patients with PFTs A c c e p t e d M a n u s c r i p t performed after clinical recovery from COVID-19 (on the day prior to hospital discharge) and at 6 weeks post-discharge showed a restrictive pattern in 10 of 13 patients with improvement after 6 weeks [14] . However, forced vital capacity was still lower than the lower limit of normal at 6 weeks postdischarge.

In the previously discussed early report of 138 hospitalized patients from Wuhan, China, cardiac manifestations were described in acute COVID-19, with acute cardiac injury occurring in 10 patients (7.2%), shock in 12 patients (8.7%), and arrhythmias in 23 patients (16.7%) [12] . The median hypersensitive troponin I (normal range <26.2 pg/ml) was 6.4 ng/ml in all hospitalized patients and 11.0 pg/ml in ICU patients.

With respect to post-acute cardiac manifestations, in a matched prospective cohort study of cardiac magnetic resonance (CMR) imaging from Germany, Puntmann et al assessed 100 patients with recently recovered COVID-19 (classified as a minimum of 2 weeks from original diagnosis with resolution of respiratory symptoms and negative PCR testing) [15] . The median time from COVID-19 diagnosis to CMR evaluation was 71 days (range 64-92 days). Compared to risk factor-matched control patients, participants who had recovered from COVID-19 had lower left ventricular ejection fraction (57% compared to 62%; p <.001) and were more likely to have detectable high-sensitive troponin T (>3 pg/mL) (71% compared to 31%; p <0.001). Irrespective of preexisting conditions, 78% of recently recovered COVID-19 patients had ongoing cardiac involvement noted on CMR, such as myocardial inflammation, regional scarring, and pericardial enhancement. The majority of patients in this study had asymptomatic (n=18) or mild to moderate (n=49) symptoms, while the remaining one-third required hospitalization. Of note, 36 (36%) patients reported ongoing shortness of breath and general exhaustion at the time of evaluation, with 25 noting symptoms during less-than-ordinary daily activity. Four of these 25 (16%) patients had been previously hospitalized. It is difficult to know, A c c e p t e d M a n u s c r i p t however, whether these subjective symptoms were due to cardiac abnormalities or concomitant pulmonary pathology.

Acute SARS-CoV-2 infection, especially in its severe form, has been shown to be associated with an increased risk for venous thromboembolism (VTE) [16] . The long-term risk of VTE, based on current knowledge, is less well-defined. A retrospective observational cohort study of 163 patients, of whom 42 (26%) required ICU admission, had a 30-day post-discharge cumulative incidence of VTE of 0.6% (95% confidence interval [CI] 0.2%-4.6%) [17] . The cumulative incidence of all thrombosis (including pulmonary embolism, left ventricular thrombus, central retinal artery occlusion, thrombosis of arterio-venous dialysis fistula, and ischemic stroke) was 2.5% (95% CI 0.8%-7.6%). The 30-day cumulative rates of major bleeding and clinically relevant non-major bleeding (using the International Society of Thrombosis and Haemostasis definitions for these conditions [18] ) were 0.7% and 2.9%, respectively. These rates are comparable to the post-discharge hospital-acquired VTE (HA-VTE) and bleeding rates, 0.3-2.5% and 0.7-2.0%, respectively, that have been observed in patients with comparable forms of non-COVID-19 acute medical illness [17, 19, 20] .

In another study of 102 patients, Engelen et al report a low rate of VTE (<1%) at a mean of 44 days after hospitalization due to COVID-19 [21] . This finding is consistent with a large review of HA-VTE in patients with COVID-19 discharged from King's College Hospital in the UK [22] . HA-VTE in this study was defined as VTE diagnosed in the hospital at least 48 hours after admission, or postoperatively, and occurring up to 90 days post-discharge. A total of 1,877 patients discharged after hospitalization for COVID-19 were included in the analysis. There were 84 HA-VTE episodes that occurred during the study period. Overall, 9/84 (11%) occurred after discharge, at a median of 8 days.

Therefore, the authors calculated the frequency of discharged patients who developed HA-VTE to be 4.8 per 1000 discharges. By comparison, the rate was found to be 3.1 per 1000 discharges in 2019, which occurred within 42 days of discharge. The odds ratio of HA-VTE associated with COVID-19 A c c e p t e d M a n u s c r i p t compared to rates observed in 2019 before COVID-19 was 1.6 (95% CI 0.8-3.1) and was not statistically significant.

The susceptibility of certain tissues and organ systems to SARS-CoV 2 might result in other postacute COVID-19 symptoms that have yet to be described. For example, SARS-CoV-2 exhibits neurotropic properties, and approximately 36% of patients with COVID-19 develop neurologic signs and symptoms, such as headaches, encephalopathy, and paresthesias [23] . Cases of confirmed SARS-CoV-2 viral encephalitis have also been documented [23, 24] . It is conceivable that there may be longterm persistent effects on the nervous system because of these acute manifestations. However, such information has not yet been reported in the medical literature.

Acute kidney injury (AKI) has been well described as a potential complication in patients hospitalized due to severe COVID-19 with rates in the United States as high as 37-40% [25, 26] . Less is known regarding long-term recovery of kidney function after the acute period. Ng et al report outcomes in 9,657 patients admitted with COVID-19 during March and April 2020 [27] . They found that AKI, both with and without need for renal replacement therapy (RRT), was significantly associated with risk of death. They also note that among the 108 patients with AKI who did require RRT and survived, 33 (31%) patients remained on dialysis at the time of discharge, suggesting prolonged kidney dysfunction despite resolution of acute COVID-19 infection. Among patients with AKI who did not require RRT, a substantial proportion (36.9%) continued to have kidney dysfunction at the time of hospital discharge. In the pre-COVID-19 era, hospital-associated AKI was shown to be associated with increased mortality and increased risk of de novo chronic kidney disease [28] .

A c c e p t e d M a n u s c r i p t

In the previously described UK study that surveyed 100 patients with COVID-19 at a mean of 48 days after hospital discharge, speech, swallow, and nutritional needs were also assessed [7] . Dysphagia was observed in 12.5% (4 of 32 patients) of ICU patients compared to 5.9% (4 of 68 patients) of ward patients, laryngeal sensitivity in 25% of ICU patients compared to 11.8% of ward patients, and voice changes in 25% of ICU patients compared to 17.6% of ward patients. Overall, the full extent and [29] .

A unique aspect of SARS-CoV-2 infection that has been reported is a condition termed multisystem inflammatory syndrome (MIS). Initially described in children and adolescents, MIS-C is thought to occur many weeks after initial mild or asymptomatic SARS-CoV-2 infection [30] . Thus, MIS-C can be thought of as part of the range of clinical situations that can potentially occur in the post-infectious or post-acute period.

In April 2020, an initial report described an inflammatory condition in 8 children resembling

Kawasaki disease (KD) [31] . Since then, numerous reports of children with the condition have appeared in the literature [30, [32] [33] [34] . The working case definition for MIS-C as put forth by CDC has multiple components: (1) patient who is <21 years of age with fever, laboratory findings of inflammation, and severe illness affecting multiple organ systems; (2) no alternative diagnosis; and

(3) evidence of SARS-CoV-2 infection as demonstrated by molecular, serological, or antigen testing (or exposure to a suspected or confirmed COVID-19 case within the 4 weeks before presentation) [35] .

A c c e p t e d M a n u s c r i p t

In the largest series to date describing MIS-C in 570 patients across the United States, approximately three-quarters of patients had serological evidence of SARS-CoV-2 infection; slightly less than half of patients had a negative PCR test for SARS-CoV-2 [36] . Additionally, among 147 patients with a positive PCR test but not positive serology, 137 of these patients actually had unknown serological test results. These data strongly suggest that MIS-C is an inflammatory condition with overlap with KD that most often occurs in the post-infectious period.

Recently, a detailed report from CDC described MIS occurring in 16 adult patients as opposed to children and adolescents [37] . In the 11 patients in whom SARS-CoV-2 antibodies were checked, all 11 had positive serology. Also, 6 of 16 patients had negative PCR test results. These findings suggest that MIS-A is also a post-acute or post-infectious phenomenon.

Post-acute symptoms have been observed in a variety of infections, such as Epstein-Barr virus, dengue fever, tick-borne encephalitis, influenza, West Nile virus, Chikungunya, Zika virus, and Ross River virus, among others [38] . With regard to epidemic coronaviruses specifically, Tansey et al assessed health outcomes in patients who had recovered from SARS-CoV up to 1 year after discharge and found that more than half of patients were continuing to experience fatigue and sleep disturbances [39] . Another 4-year follow-up study of SARS-CoV patients found that almost 50% still suffered from chronic fatigue, and over one-quarter qualified for a diagnosis of myalgia encephalitis/chronic fatigue syndrome (ME/CFS) [40] . In 2015, the National Academy of Medicine published proposed diagnostic criteria for ME/CFS [41] . Summarizing, these criteria state a patient diagnosed with ME/CFS should have the following clinical findings: (1) substantial impairment in the ability to engage in pre-illness activities for more than 6 months, along with profound fatigue not alleviated by [42] . They found that a reduction in DLCO was present in 11-45% of patients at 12 months.

Approximately one-third of patients also had persistent symptoms of PTSD, depression, and anxiety beyond 6 months following recovery.

In addition to pulmonary complications, MERS-CoV is also believed to be potentially neuroinvasive.

A study by Kim et al showed that approximately 20% of patients with MERS developed delayed neurological symptoms 2-3 weeks after typical respiratory symptoms [23, 43] . Neurological findings included encephalopathy, paralysis, ischemic stroke, Guillain-Barre syndrome, and neuropathy [23] .

Ultimately, our understanding of prolonged manifestations of different infectious diseases will likely become more robust with ongoing study of post-acute COVID-19.

Considering the broad spectrum of clinical presentation of COVID-19, the etiology of post-acute COVID-19 symptoms is likely multifactorial. For example, in SARS-CoV, the virus's potential for direct neuro-invasion was thought to lead to persistent neuropsychiatric sequelae [44] . Other proposed mechanisms for persistent sequelae of SARS-CoV and SARS-CoV-2 infections include the welldescribed virus-induced -cytokine storm‖ and dysregulated immune response [45] . Additionally, it is important to note that replication-competent virus is rarely recovered beyond 20 days after symptom onset [3] ; this suggests that persistent symptoms are driven primarily by immunological phenomena.

Another possibility is that lingering virus continues to be present in immunologically privileged sites within the body, where it can be difficult for the immune system to eradicate. Finally, in a postmortem study of histologic features of peripheral lung tissue, features of severe endothelial injury along with diffuse thrombosis with microangiopathy were observed [46] . Therefore, endothelial injury and ongoing dysfunction might also play a role in post-acute symptomatology and organ dysfunction.

A c c e p t e d M a n u s c r i p t Post-ICU syndrome, another well-described condition that includes symptoms of persistent cognitive dysfunction, acquired weakness, fatigue, dyspnea, and intrusive memories after hospital discharge, might also be a contributing factor for patients with post-acute COVID-19 symptoms whose hospitalization included ICU care [47] . Much remains to be learned about the interplay of all these potential factors and their relative contribution to persistent symptoms and organ dysfunction following acute COVID-19. The immunological origins of MIS are also a subject of ongoing research.

Overall, the available data suggest that a subset of patients who recover from acute SARS-CoV-2 infection will have longer-term sequelae from the disease, due to persistent symptomatology or prolonged organ dysfunction, or potentially through the development of new syndromes, such as MIS, that occur after initial asymptomatic or mild infection.

The full spectrum of the duration and severity of post-acute COVID-19 is currently unknown. It is quite possible that with the significant number of patients who have already contracted COVID-19 and ongoing disease transmission, post-acute COVID-19 symptomatology and organ dysfunction could be an important area of resource utilization in the future. In the rapidly evolving era of the COVID-19 pandemic, consensus is also needed regarding how to classify manifestations in the postacute period. Here, we have reviewed the existing literature on post-acute COVID-19 symptomatology, prolonged organ dysfunction, and the likely post-infectious inflammatory condition MIS, a rare complication of acute SARS-CoV-2 infection. Additionally, we have proposed a potential approach to categorizing post-acute COVID-19 into these 3 domains (Figure 1) , recognizing the potential interplay between organ pathology and symptomatology. The overall prevalence of postacute COVID-19 symptoms and its association with prolonged organ dysfunction remain unclear.

Further studies are needed to better understand post-acute COVID-19 and to help inform the multidisciplinary approach that will likely be needed to diagnose and treat this heterogeneous condition.

A c c e p t e d M a n u s c r i p t

COVID-19 Treatment Guidelines

Management of post-acute covid-19 in primary care

Duration of Isolation and Precautions for Adults with COVID-19

Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients

Asymptomatic infection and atypical manifestations of COVID-19: comparison of viral shedding duration. The Journal of Infection

Persistent symptoms in patients after acute COVID-19

Post-discharge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation

Post-discharge persistent symptoms and healthrelated quality of life after hospitalization for COVID-19

Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network-United States

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Abnormal pulmonary function in COVID-19 patients at time of hospital discharge

Pulmonary function in patients surviving to COVID-19 pneumonia

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Post-discharge thrombosis and hemorrhage in patients with COVID-19

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients

The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial

Incidence of Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalisation [abstract

Post-discharge venous thromboembolism following hospital admission with COVID-19 Blood

Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain, behavior, and immunity

ENCOVID Study Group, Clinical presentation and outcomes of SARS-CoV-2 related encephalitis: the ENCOVID multicentre study. The Journal of Infectious Diseases

Acute kidney injury in patients hospitalized with COVID-19

Acute Kidney Injury in Hospitalized Patients with COVID-19

Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury

Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury

The Stanford Hall consensus statement for post-COVID-19 rehabilitation

Multisystem inflammatory syndrome in children in New York State

Hyperinflammatory shock in children during COVID-19 pandemic

Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. The Lancet

Multisystem inflammatory syndrome in US children and adolescents

Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C)

COVID-19-associated multisystem inflammatory syndrome in children-United States

Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 Infection -United Kingdom and United States

Post-viral fatigue and COVID-19: lessons from past epidemics. Fatigue: Biomedicine, Health & Behavior

One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Archives of internal medicine

Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up

Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness

Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis

Neurological complications during treatment of middle east respiratory syndrome

Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain, behavior, and immunity

A formal analysis of cytokine networks in chronic fatigue syndrome

Pulmonary Vascular Endothlialitis, Thombosis, and Angiogenesis in Coivd-19

Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders' conference

The authors wish to thank Dr. Biykem Bozkurt for helpful discussions regarding the concepts reviewed in this manuscript.

This manuscript does not include factors necessitating patient consent.Potential conflicts of interest: P.A.K. reports receiving research funding from Vessel Health, Inc.

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t